Tags

Type your tag names separated by a space and hit enter

The endocannabinoid system in Parkinson's disease.
Curr Pharm Des 2008; 14(23):2337-47CP

Abstract

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.

Authors+Show Affiliations

Clinica Neurologica, Ospedale S. Maria della Misericordia, Universita' di Perugia, 06156 Perugia, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18781984

Citation

Di Filippo, Massimiliano, et al. "The Endocannabinoid System in Parkinson's Disease." Current Pharmaceutical Design, vol. 14, no. 23, 2008, pp. 2337-47.
Di Filippo M, Picconi B, Tozzi A, et al. The endocannabinoid system in Parkinson's disease. Curr Pharm Des. 2008;14(23):2337-47.
Di Filippo, M., Picconi, B., Tozzi, A., Ghiglieri, V., Rossi, A., & Calabresi, P. (2008). The endocannabinoid system in Parkinson's disease. Current Pharmaceutical Design, 14(23), pp. 2337-47.
Di Filippo M, et al. The Endocannabinoid System in Parkinson's Disease. Curr Pharm Des. 2008;14(23):2337-47. PubMed PMID: 18781984.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The endocannabinoid system in Parkinson's disease. AU - Di Filippo,Massimiliano, AU - Picconi,Barbara, AU - Tozzi,Alessandro, AU - Ghiglieri,Veronica, AU - Rossi,Aroldo, AU - Calabresi,Paolo, PY - 2008/9/11/pubmed PY - 2008/11/18/medline PY - 2008/9/11/entrez SP - 2337 EP - 47 JF - Current pharmaceutical design JO - Curr. Pharm. Des. VL - 14 IS - 23 N2 - Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD. SN - 1873-4286 UR - https://www.unboundmedicine.com/medline/citation/18781984/The_endocannabinoid_system_in_Parkinson's_disease_ L2 - http://www.eurekaselect.com/67572/article DB - PRIME DP - Unbound Medicine ER -